Hauser financials
This article was originally published in The Tan Sheet
Executive Summary
Supplement supplier "in discussions" to sell its Shuster Labs contract services division, which would generate funds to pay Wells Fargo Bank loans, "permit Hauser to obtain a new line of credit to finance operations," firm says July 1. Otherwise, Hauser may not be able to continue as a "going concern" due to "significant operating losses, existing deficit and lack of certainty as to a credit line," firm states. Company amended credit agreement with Wells on June 25 to provide for termination date of Aug. 31, 2002 instead of Aug. 31, 2003, in exchange for Wells agreeing to waive defaults under agreement. Hauser Q4 net revenue dipped 1.4% to $14.3 mil., with net loss of $1.5 mil., down from $23.1 mil. FY 2002 sales declined 13.6% to $57.6 mil., with $5.4 mil. net loss, compared to $33.3 mil. loss a year ago...
You may also be interested in...
Hauser restructuring
Supplement supplier announces sale of Shuster Labs contract services division to Specialized Technology Resources for $7.7 mil. cash. Proceeds from the sale will help Hauser "pay down a substantial portion of its debt," firm says; Hauser was given until Aug. 31 to pay its Wells Fargo Bank loans (1"The Tan Sheet" July 8, 2002, p. 9)...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.